KR101791034B1 - Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract of Allii Radix as effective component - Google Patents

Abstract

The present invention relates to a composition for preventing, ameliorating, or treating hyperlipidemia or hyperlipidemia-related metabolic disorders comprising an extract of T. vaginalis as an active ingredient, wherein the T. gabbana extract of the present invention has an effect of lowering uric acid in the serum of an animal model , It is not only safe because it is an active ingredient derived from natural products, but also can be widely used in industries related to hyperlipidemia or metabolic disorders related to hyperlipidemia because it is relatively easy to supply raw materials. In particular, it can be effectively used for preventing, ameliorating or treating gout or gouty arthritis.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing, ameliorating or treating hyperlipidemia or hyperlipidemia-related metabolic disorders, which comprises an extract of Panax ginseng CA Meyer as an active ingredient.

The present invention relates to a composition for preventing, ameliorating or treating hyperlipidemia or hyperlipidemia-related metabolic disorders containing an extract of T. oblongata as an active ingredient.

Hyperuricemia is defined by serum uric acid levels in men over 6.8 to 7.0 mg / dL or in women over 6 mg / dL. Hyperlipidemia and hyperlipidemia-related metabolic disorders (for example, gout) occur in 3 to 5 million people in the United States. In the United States, African Americans are twice as likely to have gout than white people. Gout and hyperuricemia are also prevalent in China, Japan, Polynesia and sub-Saharan Africa. The incidence of gout between 1990 and 2010 has nearly doubled, and the number of domestic gout patients has increased by an average of 14% per year .

Metabolic disorders associated with hyperlipidemia include not only gout but also acute, single arthritic, painful seizures of inflammatory arthritis, urinary stone calculus, nephrolithiasis and gout, due to uric acid crystals, deposits of intraurethral crystalloid crystals, Includes nephropathy. Long-term nephrolithiasis and gouty nephropathy are known to increase the risk of kidney damage and renal failure. Among the metabolic disorders associated with hyperlipidemia, gout is caused by uric acid (uric acid in the blood, body fluids, and joint fluids in the form of urate salt) as the concentration of uric acid (the product of metabolism of the substance called purine, ) Crystals are deposited on cartilage, tendons and surrounding tissues of joints. This phenomenon causes inflammation of the joints, resulting in recurrent seizures accompanied by severe pain. Deformations and deformities of the joints occur when the gouty nodules (tophi) due to urate crystals are deposited. In addition to abnormalities of the joints, kidney disease (kidney stones) that cause kidney disease and kidney stones caused by uric acid may occur.

In addition, gout occurs through stages such as asymptomatic hyperuricemia, acute gouty arthritis, intermittent gout, and chronic nodular gout. Early asymptomatic hyperuricemia has elevated serum uric acid levels, but symptoms such as arthritic symptoms, gouty nodules, and uricosuric acne have not been reported yet. Acute gouty arthritis is a stage in which at least 20 years of persistent hypercholesterolemia occurs, followed by gout attacks or kidney acrosis. The most characteristic symptoms are acute attacks of painful arthritis, And it is not accompanied by systemic symptoms, but it gradually invades the joints and accompanies heat. Intermittent gout refers to a period of time without symptoms between gout attacks. In most cases, the second seizure occurs between 6 months and 2 years after the first seizure. Depending on the treatment, Involves multiple joints. Chronic nodular gout appears to resemble other types of arthritis when it is in a period of chronic nodular ventilation past a ventilated intermittent device. There is progressive stiffness and constant pain in the joints of the affected area.

Gout is known to be a clear and successful treatment of the disease, but it is often accompanied by other diseases such as hypertension and chronic renal failure. Therefore, side effects of medication should be carefully considered, and lifestyle changes Patients' efforts are essential to improve prognosis in long-term treatment. Gout and hyperuricemia are not included in the diagnostic criteria for metabolic syndrome, which is a complex disorder with hypertension, hyperlipidemia, hyperglycemia, abdominal obesity, and clinical manifestations that increase the risk of adult diseases such as arteriosclerotic heart disease and type 2 diabetes The metabolic syndrome is thought to be closely related. In Korea, it was reported that 44% of patients with gout were accompanied by metabolic syndrome. Gout usually occurs in the form of acute monoarthritis, but may involve small joints or rarely joints. Non-steroidal anti-inflammatory drugs (NSAIDs), which are used in the treatment of acute gout, are known to inhibit the inflammatory response and are known to inhibit the activity and migration of leukocytes, ), Steroids are all drugs that can effectively treat gout attacks, and selective cyclooxygenase (COX-2) inhibitors are known to have the same effects as the existing non-steroidal anti-inflammatory drugs.

In addition, maintaining the serum uric acid concentration below the saturation level for a prolonged period of time can reduce the size of already existing ventilated nodules (tophi) as well as prevention of acute gouty arthritis. In the chronic phase of gout, uric acid is lowered in the blood, and the uric acid lowering agent is classified into xanthine oxidase (XO) inhibitor and uricosuric agent according to the mechanism. Allopurinol and febuxostat, which was recently developed as a new drug. Allopurinol is a xanthine oxidase (XO) inhibitor that can be effectively used regardless of the cause of hyperuricemia, but the most serious side effect of allopurinol is hypersensitivity syndrome, Eosinophilia, hepatitis, kidney failure, etc., are known to be at risk of death. Unlike xanthine oxidase inhibitor or allopurinol, febuxostat is also a non-purine selective blocker, which is metabolized mainly in the liver to form glucuronide. Most cases of gout are chronic, and even if there are no symptoms, treatment is done to lower the anti - inflammatory drug and uric acid concentration prophylactically. These preventive treatments should be used after the disease has been maintained for a period of time in a calm state, otherwise the ventilation will recur more severely. However, there is a lot of controversy about the proper period of the illness, and it is also difficult to prevent the acute onset of the gout, which is intermittently recurrent, and the gout is caused by natural products. Inhibition of the enzyme, an oxidase, is still insufficient.

On the other hand, Allii Radix is a fresh scaly stem of Allium fistulosum L. It has a long columnar shape, with several roots at one end, and a concentric circle with a length of 3 ~ 10cm and a diameter of 1 ~ 2cm. The outer surface is white and there is a pronounced fine parallel vein. It has a pungent smell and a little sweet taste. It grows in various parts of Korea. Known pharmacological agents include allicin and diallyl-monosulfide. Pharmacological actions include perspiration, diuretic action, cardiac action, and giddiness.

In addition, volatile components act on the enzymatic system of bacteria to inhibit the growth of Diphtheria, Mycobacterium, Mycobacterium, Staphylococcus, and Streptococcus, and the immersion agent (1: 1) inhibits the growth of various skin fungi, It has an effect of controlling the tension of blood vessels.

As a technique related to extracts of Ganoderma lucidum or hyperlipidemia, Korean Patent Laid-Open Publication No. 2005-0051627 discloses a pharmaceutical composition for prevention and treatment of gout containing Leek extract, and Chinese Patent Publication No. 102258671 discloses a natural mixture US Patent No. 8969410 discloses a pharmaceutical composition for relieving gout and treating gout.

However, a composition for preventing, ameliorating, or treating hyperlipidemia or hyperlipidemia-related metabolic disorders containing the extract of the present invention as an active ingredient has not been disclosed.

The present invention provides a composition for preventing, ameliorating or treating hyperlipidemia or hyperlipidemia-related metabolic disorders comprising an extract of Ganoderma lucidum as an active ingredient, The present invention has been accomplished by confirming that the gum extract reduces the serum uric acid in the animal model.

In order to achieve the above object, the present invention provides a health functional food for preventing or ameliorating hyperlipidemia or metabolic disorder associated with hyperlipidemia, which comprises an extract of Ganoderma lucidum as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating hyperlipidemia or hyperlipidemia-related metabolic disorders containing an extract of Ganoderma lucidum as an active ingredient.

The present invention relates to a composition for preventing, ameliorating or treating hyperlipidemia or hyperlipidemia-related metabolic disorders comprising an extract of T. gangue as an active ingredient, which reduces the uric acid content in the serum, is safe from the natural origin, , Hyperuricemia or hyperlipidemia-related metabolic disorders. In particular, it can be effectively used for preventing, ameliorating or treating gout or gouty arthritis.

FIG. 1 shows the result of confirming a decrease in urinary output in serum after administering the extract of the present invention to a normal SD-rat animal model. Normal refers to the normal animal model group, and 200 mg / kg refers to the animal model group administered with 200 mg / kg of total extract to the normal animal model.
FIG. 2 shows the result of confirming the decrease in the uric acid amount in the serum after administering the extract of the present invention to an animal model of SD-lact that induces hyperlipemia. Normal means the normal animal model group, and Control means the animal model group that induced hyperkalemia by administration of potassium oxonate.

The present invention relates to a health functional food for preventing or ameliorating hyperlipidemia or hyperlipidemia-related metabolic disorders containing an extract of Ganoderma lucidum as an active ingredient.

Preferably, the hyperlipidemia-related metabolic disorder is any one selected from acute or chronic gout, gouty redness, gouty arthritis, gouty nephrolithiasis, and gouty nephropathy, but the present invention is not limited thereto. The gustatory redness is a symptom of reddening due to inflammation due to gout.

The extract is preferably extracted using a C ₁ -C ₄ lower alcohol, water or a mixture thereof as a solvent. More preferably, the extract is extracted using ethanol as a solvent, more preferably 70% (v / v) of ethanol as a solvent, but the present invention is not limited thereto.

The health functional food for preventing or ameliorating hyperlipidemia or hyperlipidemia-related metabolic disorders containing the above extract as an active ingredient may be manufactured from any one selected from a beverage, a pill, a tablet, a capsule, and a powder, Food or food, and can be suitably prepared according to a conventional method.

Examples of foods to which the gum extract of the present invention can be added include meat products, sausages, breads, chocolate, candies, snacks, confectionery, pizza, ramen noodles, other noodles, dairy products including ice- Tea, a drink, an alcoholic beverage, and a vitamin complex, and includes all health foods in a conventional sense.

The health functional foods include various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alkynic acid and its salts, , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination.

The health functional food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.

The present invention also relates to a pharmaceutical composition for preventing or treating hyperlipidemia or hyperlipidemia-related metabolic disorders containing an extract of Ganoderma lucidum as an active ingredient.

In the above pharmaceutical composition, the hyperlipidemia-related metabolic disorder is preferably, but not limited to, any one selected from acute or chronic gout, gouty redness, gouty arthritis, gouty nephrolithiasis and gouty nephropathy. The gustatory redness is a symptom of reddening due to inflammation due to gout.

In addition to the above-mentioned effective ingredients, the composition may further include an uric acid salt lowering agent. The preferred urate reducing agent is at least one selected from xanthine oxidase inhibitor, uricosuric agent, urate oxydase, urine alkalizing agent and phenobibrate And may further comprise a pharmaceutically acceptable carrier, excipient or diluent in addition to the above extract.

The pharmaceutical composition of the present invention may be various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of suppositories include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The composition of the present invention may be administered orally or parenterally, and it is preferable to select the intraperitoneal, rectal, rectal, intravenous, intramuscular, subcutaneous, intrauterine or intracerebral injection methods for parenteral administration, It is used for external skin.

The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

The dosage of the composition of the present invention may be varied depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.

Example  One. Total  Preparation of extract

15 kg of 70% (v / v) ethanol was added to 1 kg of the total bag, and the mixture was extracted at 85 캜 for 3 hours. The filtrate was concentrated under reduced pressure at 50 캜 and dried to obtain 26.3 g of ganoderma extract.

Example  2. Normal SD - Lette  Identification of the decrease in uric acid contained in the blood in animal models

The total extract of 200 mg / kg and the positive control 50 mg / kg alopyrinol were each suspended in a 0.01 M phosphate buffered saline buffer solution containing 0.1% polyoxyethylene sorbitane monooleate, The animals were orally administered once to an SD-rat model.

After 2 hours of oral administration, blood was taken after anesthetizing with ethyl ether and the amount of uric acid was measured using uric acid assay kit (ab65344, abcam, USA).

As shown in FIG. 1, the uric acid level decreased to about 1.52 mg / dl by the administration of the extract of Ganoderma lucidum and the serum uric acid level decreased to about 46.5% Respectively.

Example  3. Analysis of the reduction effect of uric acid contained in blood in an animal model inducing hypercalcemia

To induce hyperuricemia in the SD-rat, which is an animal model inducing hypercalcemia, it was dissolved in a 0.5% sodium carboxymethylcellulose (CMC-Na, pH 5.0) solution containing 0.1 M sodium acetate And 150 mg / kg of potassium oxonate was intraperitoneally injected.

After 24 hours, urine samples (ab65344, abcam, USA) were used to urinate and the model animals with hyperuricemia induced were selected.

100 and 300 mg / kg of total extract and 50 mg / kg of allopurinol as a positive control were added to the selected model animals in 0.01 M phosphate buffered saline (PBS) containing 0.1% polyoxyethylene sorbitane monooleate saline buffer solution for 3 days and fasted for 16 hours on the day before the autopsy.

Two hours after the last oral administration, blood was taken after anesthetizing with ethyl ether, and the amount of urine acid was measured using a uric acid assay kit (ab65344, abcam, USA).

As shown in FIG. 2, uric acid amount was increased to about 4.5 mg / dl by the administration of potassium oxonate, and the total extract of the present invention was administered at 100 and 300 mg / kg / day , Respectively. As a result, it was confirmed that the amount of uric acid in serum decreased to about 2.2 and 1.6 mg / dl. That is, the amount of uric acid in the blood in the animal model of hyperlipidemia administered with the extract of Ganoderma lucidum according to the present invention is reduced by about 51 to 64% as compared with that in the hyperolipidemic animal model group.

Claims (8)

A health functional food for preventing or ameliorating hyperlipidemia or hyperlipidemia-related metabolic disorders containing an extract of Tongbaek ethanol as an active ingredient. The method according to claim 1, wherein the hyperlipidemia-related metabolic disorder is any one selected from acute or chronic gout, gouty redness, gouty arthritis, gouty nephrolithiasis, and gouty nephropathy. Or health functional food for improvement. delete A pharmaceutical composition for the prevention or treatment of hyperlipidemia or hyperlipidemia-related metabolic disorders containing an extract of ganoderma lucidum as an active ingredient. 5. The method of claim 4, wherein the hyperlipidemia-related metabolic disorder is any one selected from acute or chronic gout, gouty redness, gouty arthritis, gouty nephrolithiasis, and gouty nephropathy. Or < / RTI > The pharmaceutical composition for preventing or treating hyperlipidemia or hyperlipidemia-related metabolic disorders according to claim 4, which further comprises an uric acid-lowering agent other than the above-mentioned effective ingredient. The method according to claim 6, wherein the urate reducing agent is at least one selected from the group consisting of xanthine oxidase inhibitor, uricosuric agent, urate oxydase, urine alkalizing agent, and phenobibrate. ≪ / RTI > [Claim 5] The pharmaceutical composition according to claim 4, which further comprises a carrier, an excipient or a diluent in addition to the above-mentioned swale extract, or a prophylactic or therapeutic agent for hyperlipidemia or hyperlipidemia-related metabolic disorders.

Images